Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Reports outline immunotherapy study results from E. Jonasch et al
November 26th, 2008
According to a study from the United States, "A number of patients with renal cell carcinoma (RCC) are faced with the knowledge that, despite undergoing nephrectomy, they have a substantial risk of disease recurrence. Prior efforts to decrease recurrence risk using immunotherapy have largely been ineffective." "The reasons for the failure of immunotherapy are not clear, as our ability to measure immunological outcomes has not provided us with clues on the determinants which signal a successful antitumor effect. We are now entering the targeted therapy era, and clinical trials are underway to determine whether adjuvant or neoadjuvant targeted therapy strategies are...
Source: Immunotherapy Weekly (2008-11-26)
|
